Japan Infectious Disease Drugs Market Analysis Report 2022 to 2030

Japan Infectious Disease Drugs Market Analysis

$ 3999

Japan Infectious Disease Drugs Market valued at $7.38 Bn in 2023, projected to reach $10.23 Bn by 2030 with a 4.77% CAGR. Rising healthcare expenditure, government initiatives and funding, and technological advancements in drug development are driving the market. The market is dominated by key players like Takeda Pharmaceuticals, Daiichi Sankyo, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.

ID: IN10JPPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Aneri Parekh

Buy Now

Japan Infectious Disease Drugs Market Executive Summary

Japan Infectious Disease Drugs Market valued at $7.38 Bn in 2023, projected to reach $10.23 Bn by 2030 with a 4.77% CAGR.

The development, production, and distribution of drugs for treating infectious diseases within the Japanese market are the main objectives of the infectious disease drugs market in Japan. Japan is a highly populous nation, therefore there is always a need for efficient treatments for diseases like the flu, TB, and HIV/ AIDS. The market is driven by various variables, including government initiatives, healthcare infrastructure, and illness prevalence, and it includes a variety of items like vaccinations, antibiotics, and antivirals.

The Japanese infectious disease pharmaceuticals industry is growing gradually due to rising infectious illness rates and the government's focus on healthcare infrastructure. To combat new infectious diseases and drug-resistant strains, industry participants are increasing their product portfolios and spending on research and development of new medications. Furthermore, pharmaceutical corporations and research institutions are collaborating and forming partnerships, which are propelling innovation in the market.

The estimated worth of the global market for infectious disease medications in 2023 was $118.75 Bn. This surge is the result of both, public education campaigns on the management and prevention of infectious diseases by the government and an increase in diagnoses. A shifting market environment is indicated by the growing degree of generic competition. Long-term growth necessitates removing financial barriers and increasing access to therapy, particularly in developing countries. More industrial research and development will result from this.

Takeda Pharmaceuticals has a long history of developing and distributing vaccines along with other treatment alternatives, making it a significant player in the Japanese market for infectious disease medications. LIVTENCITY (maribavir), a cytomegalovirus (CMV) antiviral for transplant recipients, has demonstrated remarkable efficacy as of December 2023. Takeda is well-positioned in the changing field of infectious disease drugs owing to its ongoing R&D investments. Their emphasis on unmet needs, worldwide pipeline, and collaborations is projected to increase their influence in the Japanese and global markets.

Japan infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Technological Developments: Breakthroughs in molecular biology and biotechnology have made it easier to find and create novel, more potent medications for infectious diseases.

Fundings from the Government: The pharmaceutical sector experiences a surge in investment and innovation due to government assistance for research and development, as well as measures aimed at combating infectious diseases.

Growing Healthcare Expenditure: Japan's expanding healthcare spending gives patients access to more affordable infectious disease medications, which propels market expansion.

Market Restraints:

Regulatory Hurdles: Japan's lengthy and rigorous regulatory approval procedure may cause a delay in the release of novel medications treating infectious diseases.

Pricing and Reimbursement: Japan has stringent regulations on the pricing and reimbursement of pharmaceuticals, which may restrict the viability of novel medications and discourage businesses from funding the advancement of treatments for infectious diseases.

Competition from Generics: Companies attempting to promote novel treatments for infectious diseases may face difficulties due to Japan's well-established generic medicine market, particularly if generics are more reasonably priced.

Healthcare Policies and Regulatory Landscape

Cooperating with the Ministry of Health, Labour, and Welfare is the regulatory agency known as the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. The PMDA must receive the NDA dossier and the required funds. Upon examining the NDA dossier, the PMDA could request more information. If the PMDA approves the medicine with the NDA dossier, it will be authorized for distribution in Japan. Japan's drug approval procedure is extremely stringent and comprehensive. An extensive assessment of the submitted New Drug Application (NDA) is required. This process ensures that only drugs meeting the highest quality standards may be sold, which increases the complexity of drug regulation in Japan.

Competitive Landscape

Key Players:

Takeda Pharmaceuticals
Daiichi Sankyo
AbbVie Inc.
Gilead Sciences
Merck & Co.
F. Hoffman-La Roche Ltd.
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.